EWTX - CIK 0001710072
The table below shows Edgewise Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $151.39M | $126.97M | $90.91M | $54.03M | $32.19M | $14.98M |
| SG&A | $40.02M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $31.87M |
| $23.45M |
| $17.63M |
| $11.03M |
| $2.21M |
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M | -$17.19M |
| Income tax | $4.00K | $3.00K | $4.00K | $0.00 | $0.00 | - |
| Net income | -$167.79K | -$133.81K | -$100.16K | -$67.64M | -$42.81M | -$17.12M |
| EPS (diluted) | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 | -$23.17 |